Meningococcal groups A + C + W135 + Y vaccine

Refrigerated Storage · New Medicines ·
420261000

Refrigerated Storage

Menveo · GSK

GSK
Menveo
Powder and solution for solution for injection in a vial

In the event of an inadvertent temperature excursion the following data may be used:
A maximum cumulative time of 120 hours is permitted for the vaccine vials to be stored at temperatures above 8°C through 25°C
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Contact GSK in cases where the product has been exposed to temperature deviation other than described above. Refer to the current BNF for company contact details.

No, if exposed to conditions as described above
Yes, if exposed to conditions described above
19th December 2019
London Medicines Information Service

Nimenrix · Pfizer limited

Pfizer limited
Nimenrix
Powder and solvent for solution for injection in pre-filled syringe and ampoules

Contact Pfizer in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

3rd August 2020
London Medicines Information Service

New Medicines

MenQuadfi · Meningitis ACYW prevention in toddlers and above

Information

MenQuadfi
Vaccine
Sanofi
Sanofi

Development and Regulatory status

Approved (Licensed)
Approved (Licensed)
Approved (Licensed)
Nov 20 · Nov 20: The EC has approved MenQuadfi [8].
Sep 20 · Recommended for EU approval by CHMP - the full indication is "for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y. The use of this vaccine should be in accordance with official recommendations" [7].
Apr 20 · Approved in US [6].
Oct 19 · Filed in EU via centralised procedure [5].
Jul 19 · Is now pre-registration in the US for use in children aged 2 years and over; EU filings for use in children aged 12 months and older remain planned for 2019 [4].
Feb 19 · EU submission expected 2019 [1].

Category

A quadrivalent meningococcal polysaccharide vaccine, conjugated to tetanus toxoid
UK cases of meningococcal meningitis occur mostly in younger people, and fatality rates have fallen in recent years due to the introduction of vaccination programmes covering infants and older children; annual incidence of invasive disease reported in 2012 was 2 per 100,000 [3].
Meningitis ACYW prevention in toddlers and above
Intramuscular

Trial or other data

Mar 19 · PIII trials show efficacy alone, and a series of further PIII trials is in progress to confirm efficacy when given concurrently with other paediatric vaccines (NCT03547271, NCT03691610, NCT03673462, NCT03537508) [2].